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ABSTRACT 30 
Background: Commonalities in the core symptoms of fatigue and cognitive dysfunction 31 
experienced by chronic fatigue syndrome (CFS, also known as ‘ME’) and multiple sclerosis 32 
(MS) patients have been described. Many CFS and MS patients also experience chronic pain, 33 
which has been attributed to central sensitization in both groups of patients. However, the 34 
characteristics of pain in CFS and MS patients have not been compared. 35 
Objectives: To compare experimental pain measurements in CFS and MS patients and 36 
healthy controls. 37 
Study design: Observational study 38 
Setting: This study took place in Belgium at Vrije Universiteit Brussel and the University of 39 
Antwerp. 40 
Methods: Pressure pain thresholds, temporal summation, conditioned pain modulation, and 41 
occlusion cuff pressure thresholds rated as painful (1st cuff pressure threshold) and as 3/10 on 42 
verbal numerical scale (2nd cuff pressure threshold) were measured in CFS patients (n=48), 43 
MS patients (n=19) and healthy pain-free controls (n=30). Adjusted between-group 44 
differences were estimated using linear regression models. 45 
Results: Finger pain pressure thresholds of CFS patients, compared with MS patients, were 46 
25% lower (difference ratio 0.75 (95% CI 0.59, 0.95), p=0.02) and shoulder pain pressure 47 
thresholds were 26% lower (difference ratio 0.74 (0.52, 1.04), p=0.08). Compared with MS 48 
patients, CFS patients had 29% lower 1st cuff pressure threshold (difference ratio 0.71 (0.53, 49 
0.94), p=0.02) and 41% lower 2nd cuff pressure threshold (0.59 (0.41, 0.86), p=0.006). 50 
Finger temporal summation was higher in CFS than in MS patients (mean difference 1.15 51 
(0.33, 1.97), p=0.006), but there were no differences in shoulder temporal summation or 52 
conditioned pain modulation at either site. Differences between CFS and MS patients tended 53 
to be greater than between either patient group and healthy controls. pain pressure thresholds 54 
and cuff pressure thresholds tended to be positively correlated, and temporal summation 55 
negatively correlated, with higher physical function and lower fatigue in both groups of 56 
patients. Subjective pain in CFS but not in MS patients was strongly negatively correlated 57 
with pain pressure thresholds and cuff pressure thresholds, and positively correlated with 58 
temporal summation. 59 
Limitations: The main limitations of our study are the relatively small sample sizes, its 60 
cross-sectional design, and its exploratory nature. 61 
Conclusions: We found differences in the characteristics of pain symptoms reported by CFS 62 
and MS patients, which suggest different underlying mechanisms. Specifically, overactive 63 
endogenous pain facilitation was characteristic of pain in CFS but not in MS patients, 64 
suggesting a greater role for central sensitization in CFS. 65 
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INTRODUCTION 69 
Chronic fatigue syndrome (CFS), also known as ‘myalgic encephalomyelitis’ (ME), is 70 
characterized by persistent or recurrent debilitating fatigue that is not explained by other 71 
conditions, and that results in a substantial reduction in daily activity (1). Almost all CFS 72 
patients present with the three cardinal symptoms of post-exertional malaise, cognitive 73 
dysfunction and disturbed/unrefreshing sleep, one fifth of adult CFS patients also present 74 
with muscle and joint pain as predominant symptoms (2), and approximately one third have 75 
co-morbid fibromyalgia (FM) (3). 76 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous 77 
system, manifesting as a neurological disorder in adults. Fatigue, cognitive dysfunction and 78 
pain are three of the most common MS symptoms, with significant impact on overall quality 79 
of life (4-6). Two thirds of MS patients report fatigue as being one of the most debilitating 80 
symptoms of the disease (7), 45–65% of patients with MS exhibit cognitive deficits on 81 
clinical assessment (8), and a similar proportion experience pain (9). 82 
Commonalities in the core symptoms experienced by CFS and MS patients have prompted a 83 
wide range of studies in which characteristics of the two patient groups have been compared. 84 
The motivation for these studies is that MS is a disease of known neurologic pathology, 85 
whereas there are few, if any, clues as to aetiopathology of CFS. Similarities and differences 86 
in pain experienced by CFS and MS patients have yet to be explored as a potential means of 87 
gaining insight into the causal background of pain symptoms. In particular, central 88 
sensitization, i.e. increased excitability of the central nervous system, has been demonstrated 89 
in CFS (10,11), and has been posited to play a role in MS, albeit on the basis of one study 90 
which reported widespread hyperalgesia in MS patients (12). Central sensitization is 91 
characterized by impaired endogenous pain inhibition (13) and overactive endogenous pain 92 
facilitation (14). If central sensitization explains part of the pain experienced by patients with 93 
MS, then these patients should present with poorer functioning of endogenous pain inhibition 94 
and/or overactive endogenous pain facilitation. 95 
In this study we measured widespread pressure hyperalgesia, deep tissue hyperalgesia, 96 
endogenous pain facilitation, and endogenous pain inhibition in CFS and MS patients and 97 
healthy pain-free controls. We also investigated whether there were any between-group 98 
differences in the relationships between these experimental pain measures and self-reported 99 
patient characteristics. We hypothesized that patients with CFS and MS, compared to 100 
controls, would present with poorer functioning of endogenous pain inhibition and/or with 101 
overactive endogenous pain facilitation. In addition, if these mechanisms contribute to the 102 
pain experience in people with CFS and/or MS, then we would expect the corresponding pain 103 
measurements to be associated with clinical characteristics of CFS and MS patients, such as 104 
fatigue, physical and mental function, and overall health status. 105 
 106 
METHODS 107 
Study design and setting 108 
This blinded observational study took place at the Pain in Motion research labs in Antwerp 109 
and Brussels. The study was approved by the ethics committees of the University Hospital 110 
Brussels/Vrije Universiteit Brussel and the University Hospital Antwerp, and written 111 
informed consent was obtained from all participants prior to commencement of the study. 112 
Participants 113 
General eligibility 114 
All study participants had to be Dutch speaking and aged 18-65 years. To preclude 115 
confounding factors, participants could not suffer from intellectual disabilities and women 116 
could not be pregnant or <12 months postnatal. Participants were asked to stop anti-117 
depressive, anti-epileptic and opioid pain medication two weeks prior to study participation, 118 
and not to undertake physical exertion and to refrain from taking analgesics and consuming 119 
caffeine, alcohol or nicotine on the days of the assessments. 120 
CFS patients 121 
Patients with CFS were recruited from a practice for internal medicine in Ghent (Belgium), 122 
through advertisements placed in the newsletter of a local patient support group, and during 123 
pain information sessions which are held on behalf of patient support groups. Written 124 
confirmation of a CFS diagnosis as defined by the United States Centres for Disease Control 125 
and Prevention (CDC) 1994 criteria for CFS was required from each participant’s physician 126 
(1). 127 
MS patients 128 
Patients fulfilling the McDonald diagnostic criteria for MS (15) were recruited through the 129 
neurology department of the University Hospital of Antwerp. All patients were recruited via a 130 
specialist neurologist who had extensive experience in the diagnosis and treatment of MS. 131 
Patients had to have an Expanded Disability Status Scale (EDSS) score <6 (16) and to be 132 
relapse free in the last 3 months. No constraints were placed on type of MS. 133 
Healthy controls 134 
Healthy [pain-free and without any (chronic) disease] inactive control persons were recruited 135 
from among relatives, friends or acquaintances of researchers, students, university personnel 136 
or study participants. “Inactive” was defined as working in an occupation that did not require 137 
moderate to intense physical labour and performing a maximum of three hours of moderate 138 
physical activity/week. Moderate physical activity was defined as activity demanding at least 139 
three times the amount of energy expended passively (17). 140 
Assessments and measurements 141 
The study comprised two standardized assessment sessions separated by seven days. All 142 
assessments were performed by the same researchers who were blinded to whether 143 
participants were patients or controls. Informed consent and baseline clinical and 144 
demographic characteristics were collected at the first assessment. Seven days later, muscle 145 
strength and recovery and experimental pain measurements were made, and participants were 146 
asked to complete a range of questionnaires. 147 
Patient-reported measures (questionnaires) 148 
Overall health status 149 
The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) is a health-related 150 
quality of life (HRQOL) instrument composed of 8 multi-item scales which can be 151 
aggregated into two summary measures: the Physical (PCS) and Mental (MCS) Component 152 
Summary scores (18). Higher scores represent better health. The SF-36 is one of the most 153 
frequently used patient-reported measures in the assessment of adults with CFS (19). 154 
Fatigue  155 
The Checklist Individual Strength (CIS) contains 20 items which measure 4 dimensions of 156 
fatigue: (1) subjective fatigue severity; (2) reduced concentration; (3) reduced motivation; (4) 157 
reduced physical activity (20). Respondents indicate, on a 7-point Likert scale, the degree to 158 
which each item was true for them in the 2 weeks preceding the assessment. Higher scores 159 
represent a higher level of fatigue and lower levels of concentration, motivation, and physical 160 
activity. The CIS has good discriminative validity, and its four dimensions have excellent 161 
consistency (Cronbach’s α 0.83-0.92) (20,21). 162 
Depression 163 
The Beck Depression Inventory for Primary Care (BDI-PC) is a 7-item instrument used for 164 
the assessment of depressive symptoms. Each item contains 4 statements, and respondents are 165 
asked to indicate the statement that best suits their feelings for the past 2 weeks including 166 
today. Within each item statements are rated on a 4-point scale ranging from 0 to 3. The BDI-167 
PC is scored by summing all of the highest ratings for each item (maximum score 21). The 168 
BDI-PC has high internal-consistency (Cronbach’s α of 0.85) (22). 169 
Self-reported pain severity 170 
The CFS Symptom List (23), comprising visual analogue scales (100 mm) for 19 of the most 171 
common CFS symptoms, was used to obtain a subjective measure of current levels of pain. 172 
Experimental pain measurements 173 
Widespread pressure hyperalgesia: pressure pain thresholds 174 
Pressure pain thresholds were measured at the middle of the right trapezius belly (shoulder 175 
pain pressure threhold) and at the dorsal surface of the right hand middle finger midway 176 
between the first and second distal joint (finger pain pressure threshold) with an analogue 177 
Fisher algometer (Force Dial, Wagner Instruments, Greenwich CT, USA) (24). Participants’ 178 
pain pressure thresholds were determined by increasing the pressure provided by the 179 
algometer (at a rate of 1kg/s) until the point the sensation first became painful (participants 180 
were instructed to say ‘stop’ at this point). This was performed twice (30s apart) at the 181 
shoulder and at the finger in order to calculate the mean pain pressure threshold for each site. 182 
Pressure algometry has been found to be efficient and reliable in the exploration of 183 
pathophysiological mechanisms involved in pain (25). 184 
Deep-tissue hyperalgesia: occlusion cuff pressure 185 
Cuff pressure thresholds were assessed by inflating an occlusion cuff placed around the left 186 
arm. The cuff served as the conditioning stimulus in the conditioned pain modulation 187 
measurement. Cuff inflation was increased manually and at a constant rate (20mmHg/s) until 188 
the participant reported the sensation becoming painful - participants were instructed to say 189 
‘stop’ – and the pressure at this point was recorded as ’1st cuff pressure threshold’. 190 
Participants then adapted to the stimulus for 30 seconds and rated the pain on a verbal 191 
numerical rating scale (VNRS) ranging from 0 (no pain) to 10 (worst possible pain). Cuff 192 
inflation was then adjusted until participants indicated pain at a level 3/10 on the VNRS, and 193 
the pressure at this point was recorded as ’2nd cuff pressure threshold’. 194 
Endogenous pain facilitation: temporal summation 195 
Temporal summation was examined 2min after the final pain pressure threshold was taken at 196 
each site (finger and shoulder). Participants were given ten pulses to the previously 197 
determined mean pain pressure threshold intensity and this pressure was maintained for 1s 198 
before being released. Pressure was increased, from zero until the predetermined intensity, at 199 
a rate of approximately 2kg/s for each pulse and pulses were presented with an interstimulus 200 
interval of 1s. After the 1st, 5th and 10th pulse, the participant was asked to rate his/her pain 201 
on the VNRS. The outcome measure for temporal summation is the difference between the 202 
tenth and the first VNRS score (24). 203 
Endogenous pain inhibition: conditioned pain modulation 204 
To assess conditioned pain modulation, temporal summation measures were taken while an 205 
occlusion cuff was inflated to a painful intensity and maintained at that level on the opposing 206 
(left) arm (as a heterotopic noxious conditioning stimulus). The cuff was inflated at 207 
approximately 20mmHg/s until the point the sensation first became painful (participants were 208 
instructed to say ‘stop’ at this point). Next, they adapted for 30 seconds to the stimulus and 209 
subsequently rated their pain on a VNRS. Cuff inflation was then increased or decreased until 210 
the participant indicated the pain level was equal to 3/10 on the VNRS. The left arm was then 211 
rested on a table and conditioned pain modulation was assessed by replicating the temporal 212 
summation assessment as described above. The outcome measure for conditioned pain 213 
modulation is the difference between the VNRS score from the first temporal summation 214 
pulse before cuff inflation and the VNRS score from the first temporal summation pulse 215 
when the arm was resting with the cuff inflated (24). 216 
Statistical analysis 217 
Participant characteristics were compared using Chi-squared and Kruskal-Wallis tests. 218 
Experimental pain measures were fitted as dependent variables in linear regression models, 219 
with group, age and sex as independent variables. Comparisons between the two patient 220 
groups were also adjusted for duration of illness. Pain pressure thresholds and cuff pressure 221 
thresholds yielded non-normal residuals and were log-transformed. For these two variables, 222 
we reported geometric means and estimated between-group percentage differences (as a 223 
difference ratio (DR)). For temporal summation and conditioned pain modulation, we 224 
reported arithmetic means and estimated between-group mean differences. We calculated 225 
pairwise correlation coefficients between the experimental pain measurements and each of 226 
the patient-reported measures, with evidence of correlation assessed by unadjusted and 227 
Bonferroni-adjusted P-values. All analyses were performed using Stata (StataCorp. 2013. 228 
Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). 229 
 230 
RESULTS 231 
Participant characteristics  232 
All groups were comparable for age (Table 1). Two MS patients had secondary progressive 233 
MS, one receiving treatment (Rebif®). The other 17 MS patients had relapsing remitting MS, 234 
with a median (IQR) interval between last relapse and experimental pain measurements of 55 235 
(18-76) months. Of these 17 patients, 11 were receiving treatment (1 on Avonex®, 2 on 236 
Copaxone®, 2 on Gilenya®, 2 on Rebif®, and 4 on Tysabri®. There was a higher proportion 237 
(96%) of female patients in the CFS group, compared with the MS (68%) and control (64%) 238 
groups. Compared with MS patients, CFS patients had a longer disease duration (median 106 239 
vs 60 months). A higher proportion of CFS patients (65%) were ‘professionally inactive’ (not 240 
in employment or education) compared with 26% of MS patients and 23% of healthy 241 
controls. CFS patients had the lowest HRQOL scores, the highest fatigue, depression and 242 
pain scores, and the greatest impairment of concentration and physical activity (highest CIS 243 
scores). MS patients had lower motivation scores than CFS patients. 244 
 245 
Experimental pain measurements  246 
CFS patients had lower pain pressure thresholds than controls and MS patients (Table 2). 247 
Finger pain pressure thresholds of CFS patients were 12% lower compared with controls 248 
(difference ratio (DR)=0.88 (95% CI 0.74-1.05), p=0.15) and 25% lower compared with MS 249 
patients (DR=0.75 (0.59-0.95), p=0.02); shoulder pain pressure thresholds were 29% lower 250 
compared with controls (DR=0.71 (0.56-0.90), p=0.005) and 26% lower compared with MS 251 
patients (DR=0.74 (0.52-1.04), p=0.08). 252 
Deep-tissue hyperalgesia measurements indicated pain experienced at 23% lower 2nd cuff 253 
pressure threshold for CFS patients compared with controls (DR=0.77 (0.59-1.00), p=0.05) 254 
and 41% lower 2nd cuff pressure threshold compared with MS patients (DR=0.59 (0.41-255 
0.86), p=0.006). 1st cuff pressure threshold was 29% lower for CFS patients compared with 256 
MS patients (DR=0.71 (0.53-0.94), p=0.02), with weaker evidence of differences between 257 
CFS patients and healthy controls (DR=0.86 (0.70-1.07), p=0.17) and between MS patients 258 
and healthy controls (DR=1.23 (0.95-1.58), p=0.12). 259 
Temporal summation measurements indicated that the greatest increase in pain (difference 260 
between 10th and 1st VNRS score) was in CFS patients (difference=1.88 (1.28-2.47)), 261 
followed by controls (difference=1.33 (0.91-1.76)) and then MS patients (difference=1.08 262 
(0.43-1.72)). Compared with controls, temporal summation in fingers was higher in CFS 263 
patients (difference=0.57 (-0.13-1.27), p=0.11) and lower in MS patients (difference=-0.82 (-264 
1.66-0.02), p=0.06), and there was particularly strong evidence for a difference between CFS 265 
and MS patients (difference=1.15 (0.33-1.97), p=0.006). There were no between-group 266 
differences for temporal summation measured in shoulders, or for conditioned pain 267 
modulation measured at either site. 268 
 269 
Correlations between experimental pain measurements and patient-reported 270 
characteristics 271 
There were few consistent or strong pairwise correlations between experimental pain 272 
measurements and patient-reported characteristics (Table 3), with the SF-36 physical 273 
component score (higher score=higher functioning) tending to be positively correlated with 274 
higher pain thresholds (pain pressure and cuff pressure) and negatively associated with 275 
temporal summation in both patient groups, and CIS physical activity score (higher 276 
score=lower functioning) showing the same correlations but with opposite signs. Subjective 277 
fatigue severity also showed the same pattern in both patient groups, tending to be negatively 278 
correlated with higher pain thresholds and positively associated with temporal summation. 279 
Subjective pain in CFS patients was strongly negatively correlated with pain pressure 280 
thresholds and cuff pressure thresholds, and positively correlated with temporal summation. 281 
There were no strong correlations between subjective pain and experimental pain 282 
measurements in MS patients. 283 
 284 
DISCUSSION 285 
To our knowledge, this is the first study comparing experimental pain measurements between 286 
groups of CFS patients, MS patients and healthy pain-free controls. Our study has shown that 287 
there were greater differences between CFS and MS patients in some experimental pain 288 
measurements than between either patient group and controls. Specifically, we observed 289 
lower pain pressure thresholds (indicating widespread pressure hyperalgesia), lower cuff 290 
pressure thresholds (indicating deep-tissue hyperalgesia), and enhanced temporal summation 291 
(indicating poorer functioning of endogenous pain facilitation) in fingers (but not in 292 
shoulders) in CFS compared with MS patients. There were no between-group differences in 293 
conditioned pain modulation, i.e. no differences in endogenous pain inhibition. These results 294 
show that overactive endogenous pain facilitation is characteristic of pain symptoms in CFS, 295 
but not in MS. This is consistent with central sensitization being the predominant pain type in 296 
CFS, but not in MS, although we cannot discount predominantly neuropathic pain in MS 297 
patients evolving over time to a state of predominant central sensitization pain as a result of 298 
abnormal central pain processing. 299 
The presence of widespread hyperalgesia in people with CFS is not a novel finding 300 
(10,26,27), but this aspect of pain has only recently been reported in people with MS (12). 301 
The exact mechanisms underlying pain and widespread hyperalgesia in MS have not been 302 
elucidated. The presence of structural lesions in the central nervous system (the 303 
spinothalamic tract), causing increased neuronal excitability at the site of injury or at remote 304 
sites, resulting in a state of hyperexcitability (central sensitization) has been one hypothesis 305 
(28). By contrast with the findings of Fernández-de-las-Peñas et al. (12), we did not observe 306 
widespread pressure hypersensitivity in our study sample of MS patients. The presence of 307 
widespread pain hypersensitivity in people with MS may only be a feature of sensory 308 
disturbances related to damage affecting the somatosensory system and, in patients with 309 
predominantly neuropathic pain, endogenous pain facilitation and inhibition could be normal. 310 
Our study follows on from two earlier studies which used the same patient groups (29,30). 311 
The first of these two studies showed that CFS patients scored higher on symptom severity 312 
and worse on handgrip strength, muscle recovery, and cognitive performance compared to 313 
MS patients and controls (29). Conditioned pain modulation efficiency represents an 314 
important brain-orchestrated inhibitory mechanism of pain processing (30), with higher 315 
conditioned pain modulation values reflecting a more efficient pain inhibitory response. 316 
Interestingly, in our study we found no differences in conditioned pain modulation either 317 
between patients and controls or between CFS and MS patients. In the CFS group this result 318 
is consistent with the study of Meeus et al. (31), who used the same conditioned pain 319 
modulation assessment protocol as we did. However, in an earlier study using a different 320 
protocol (immersion/withdrawal of the arm from warm water) , dysfunctional conditioned 321 
pain modulation was identified in CFS patients compared with controls (13). These 322 
contrasting results could be explained by the measurement method. Conditioned pain 323 
modulation is a reliable psychophysiological measurement for studying endogenous 324 
analgesia, but the degree of reliability is dependent on stimulation parameters and study 325 
methodology (32). We used a combination of ischemic pressure and mechanical pressure 326 
pain thresholds, whilst other studies have applied heat stimuli (13,33), cold water (34) or 327 
electricity (35).The endogenous pain modulatory system has not been studied in detail in 328 
relation to MS, and we are not aware of previous studies looking at the efficiency of the 329 
conditioned pain modulation mechanism in people with MS. Svendsen et al. observed a 330 
higher frequency of temporal summation (endogenous pain facilitation) in MS patients with 331 
chronic pain compared to MS patients without chronic pain (36). Our study sample of people 332 
with MS did not report significant pain complaints (29). Indeed, cuff pressure thresholds and 333 
temporal summation in the MS group tended to indicate, albeit weakly, less pain than the 334 
pain-free control group. By contrast, CFS patients reported quite high levels of subjective 335 
pain, which was strongly correlated with experimental pain measures in CFS patients. It 336 
could be argued that this between-group variation in ‘baseline’ subjective pain may explain 337 
the differences that we observed in experimental pain measurements between CFS and MS 338 
patients, but this would not explain why we found greater differences between CFS and MS 339 
patients than between CFS patients and controls. 340 
Pain is a multidimensional phenomenon and self-reported pain (pain perception) is 341 
undoubtedly influenced by patients’ previous experiences and beliefs. Negative pain-related 342 
cognitions and beliefs are common in CFS, and we previously found significantly higher 343 
negative illness cognitions in the CFS group compared with the MS group (29), which may 344 
(in part) explain why self-reported pain was lower in our MS sample.  345 
One strength of our study is that controls had to be inactive, because it is known that CFS 346 
patients, in general, have a more sedentary lifestyle (37). Hence, observed differences could 347 
not be due to a higher activity level of the control group. To ensure generalizability, CFS and 348 
MS patients were diagnosed according to established criteria, and MS patients were seen by a 349 
specialist neurologist. The main limitations of our study are its cross-sectional design and 350 
small samples, defined by earlier studies designed to investigate recovery of muscle function. 351 
We did not have data on the characteristics of patients who were not recruited or who did not 352 
wish to participate in the study hence, we were not able to assess the representativeness of 353 
our sample in relation to the respective patient populations. Asking patients to stop taking 354 
pain medication two weeks prior to the study may have introduced a selection bias into our 355 
patient groups if patients who experienced higher levels of pain felt unable to participate. The 356 
2-week wash-out period for medications may not have been long enough for all types of drug, 357 
and might have introduced bias into our findings if, for example, analgesic medications and 358 
oral contraceptives inhibit conditioned pain modulation and were used differentially across 359 
the patient and/or control groups (38). Sex differences and longer disease duration in patients 360 
with CFS may partly explain the observed differences, although our estimates were adjusted 361 
for these variables. 362 
 363 
CONCLUSION 364 
Our results do not support the hypothesis that patients with CFS and MS, compared to 365 
controls, will present with poorer functioning of endogenous pain inhibition and/or with 366 
overactive endogenous pain facilitation. Instead, we found evidence only of enhanced 367 
endogenous pain facilitation in CFS compared with MS patients. Although pain is a 368 
commonly-reported symptom in both diseases, our results suggest that there are important 369 
differences in the underlying mechanisms, and experience, of pain in CFS and MS. 370 
371 
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Table 1: Demographic, clinical and patient-reported characteristics of participants 
 HC (n=39) MS (n=19) CFS (n=48) P-valuea 
Age (years), median (range) 40 (19 – 61) 40 (25 – 59) 41 (19 – 59) P=0.56 
Female, n (%) 25 (64.1%) 13 (68.4%) 46 (95.8%) P<0.001 
Body Mass Index (kg/m2), median (IQR) 23.0 (20.3 – 28.6) 23.9 (21.1 – 25.8) 24.5 (20.8 – 27.4) P=0.82 
Disease Duration (months), median (IQR) n/a 60 (16 – 288) 106 (8 – 864) P=0.02 
Occupational status ‘inactive’, n (%) 9 (23.1%) 5 (26.3%) 31 (64.6%) P<0.001 
Anti-depressant medication, n (%) 0 (0.0%) 1 (5.3%) 8 (16.7%) P=0.01 
Pain medication, n (%) 1 (2.6%) 0 (0.0%) 0 (0.0%) P=0.55 
SF-36 mental component (0-100), median (IQR) 85 (80 – 91) 76 (48 – 87) 52 (31 – 61) P<0.001 
SF-36 physical component (0-100), median (IQR) 89 (80 – 94) 62 (44 – 80) 32 (23 – 39) P<0.001 
CIS subjective fatigue severity, median (IQR) 20 (13 – 32) 38 (26 – 46) 52 (46.5 – 55) P<0.001 
CIS reduced concentration, median (IQR) 11 (5 – 19) 23 (19 – 26) 28 (25 – 32.5) P<0.001 
CIS reduced motivation, median (IQR) 8 (5 – 14) 14 (7 – 20) 12 (10 – 19) P<0.001 
CIS reduced physical activity, median (IQR) 7 (3 – 12) 12 (6 – 15) 15.5 (11 – 19) P<0.001 
BDI-PC, median (IQR) 1 (0 – 2) 1 (0 – 3) 2.5 (1 – 5) P<0.001 
Visual analogue subjective pain rating (0-100) 6 (0 – 16) 6 (0 – 27) 49 (22 – 66) P<0.001 
aKruskal-Wallis test for medians, Fisher’s exact test for proportions; SF-36 = Medical Outcomes Study 36-Item Short-Form Health Survey; CIS = Checklist 
Individual Strength; BDI-PC = Beck Depression Inventory for Primary Care
Table 2: Experimental pain measurements (mean (95% CI)) and between-group differences, 
comparing multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients with healthy 
controls and comparing CFS patients with MS patientsa 
 HC (n=39) MS (n=19) CFS (n=48) 
Pain pressure threshold 
finger (kg/cm2) 
6.77 (6.08, 7.54) 7.63 (6.43, 9.06) 5.60 (4.92, 6.38) 
Difference (ratio) comparing patients with HCb 1.12 (0.91, 1.38), p=0.28 0.88 (0.74, 1.05), p=0.15 
Difference (ratio) comparing CFS vs MSc 0.75 (0.59, 0.95), p=0.02 
Pain pressure threshold 
shoulder (kg/cm2) 
3.78 (3.32, 4.31) 3.54 (2.80, 4.48) 2.47 (2.06, 2.96) 
Difference (ratio) comparing patients with HCb 0.93 (0.70, 1.23), p=0.60 0.71 (0.56, 0.90), p=0.005 
Difference (ratio) comparing CFS vs MSc 0.74 (0.52, 1.04), p=0.08 
1st cuff pressure 
threshold (mmHg) 
167 (145, 193) 205 (177, 237) 135 (115, 157) 
Difference (ratio) comparing patients with HCb 1.23 (0.95, 1.58), p=0.12 0.86 (0.70, 1.07), p=0.17 
Difference (mean) comparing CFS vs MSc 0.71 (0.53, 0.94), p=0.02 
2nd cuff pressure 
threshold (mmHg) 
131 (110, 155) 159 (128, 198) 88 (72, 107) 
Difference (ratio) comparing patients with HCb 1.23 (0.89, 1.70), p=0.20 0.77 (0.59, 1.00), p=0.05 
Difference (mean) comparing CFS vs MSc 0.59 (0.41, 0.86), p=0.006 
Temporal summation 
finger 
1.62 (1.06, 2.17) 0.82 (0.40, 1.23) 2.20 (1.77, 2.63) 
Difference (mean) comparing patients with HCb -0.82 (-1.66, 0.02), p=0.06 0.57 (-0.13, 1.27), p=0.11 
Difference (mean) comparing CFS vs MSc 1.15 (0.33, 1.97), p=0.006 
Temporal summation 
shoulder 
1.33 (0.91, 1.76) 1.08 (0.43, 1.72) 1.88 (1.28, 2.47) 
Difference (mean) comparing patients with HCb -0.24 (-1.18, 0.69), p=0.61 0.34 (-0.43, 1.12), p=0.38 
Difference (mean) comparing CFS vs MSc 0.34 (-0.78, 1.46), p=0.54 
Conditioned pain 
modulation finger 
0.00 (-0.25, 0.25) -0.29 (-0.90, 0.32) -0.05 (-0.44, 0.33) 
Difference (mean) comparing patients with HCb -0.25 (-0.89, 0.38), p=0.43 0.03 (-0.50, 0.56), p=0.91 
Difference (mean) comparing CFS vs MSc 0.31 (-0.49, 1.11), p=0.44 
Conditioned pain 
modulation shoulder 
-0.03 (-0.43, 0.38) -0.05 (-0.58, 0.47) 0.10 (-0.28, 0.49) 
Difference (mean) comparing patients with HCb -0.10 (-0.79, 0.59), p=0.77 -0.06 (-0.63, 0.51), p=0.84 
Difference (mean) comparing CFS vs MSc 0.01 (-0.74, 0.76), p=0.97 
a Values shown for pain pressure thresholds and cuff pressure thresholds are geometric means, and differences between 
groups are relative differences, interpreted as % increase/decrease compared with HC, e.g. 1.25 = 25% higher, 0.75 = 
25% lower. Values shown for temporal summation and conditioned pain modulation are arithmetic means, and 
differences between groups are absolute (mean) differences. 
b Adjusted for age and sex 
c Adjusted for age, sex and duration of illness
Table 3: Pairwise correlations between experimental pain measurements and patient-reported characteristicsa 
a Pearson correlation coefficients, *P<0.05, **P<0.007 (Bonferroni-adjusted P<0.05); SF-36 = Medical Outcomes Study 36-Item Short-Form Health Survey; CIS = 
Checklist Individual Strength; BDI-PC = Beck Depression Inventory for Primary Care 
 Pain pressure 
threshold finger 
Pain pressure 
threshold 
shoulder 
1st cuff pressure 
threshold 
2nd cuff pressure 
threshold 
Temporal 
summation 
finger 
Temporal 
summation 
shoulder 
Conditioned 
pain modulation 
finger 
Conditioned 
pain modulation 
shoulder 
 MS CFS MS CFS MS CFS MS CFS MS CFS MS CFS MS CFS MS CFS 
SF-36 mental component 0.29 0.08 0.27 0.04 0.26 0.18 0.31 0.14 -0.37 -0.16 -0.33 -0.06 -0.10 0.12 0.28 -0.03 
SF-36 physical component 0.47* 0.23 0.34 0.31* 0.21 0.35* 0.34 0.29* -0.29 -0.36* -0.24 -0.23 -0.11 -0.01 0.09 -0.08 
CIS subjective fatigue severity -0.38 -0.28* -0.35 -0.31* -0.27 -0.20 -0.38 -0.22 0.26 0.34* 0.32 0.21 0.03 -0.18 -0.07 0.06 
CIS reduced concentration 0.01 -0.07 0.09 -0.03 0.30 -0.07 0.04 -0.09 0.05 0.09 0.02 0.04 0.28 -0.01 -0.01 -0.10 
CIS reduced motivation -0.29 -0.07 -0.24 -0.07 0.07 -0.13 -0.19 -0.19 0.02 0.07 -0.25 0.11 -0.05 -0.04 -0.05 0.03 
CIS reduced physical activity 0.03 -0.28* 0.09 -0.25 0.21 -0.23 -0.19 -0.17 0.04 0.42** -0.07 0.29* 0.18 -0.21 -0.14 0.08 
BDI-PC 0.03 -0.05 0.03 -0.02 -0.32 -0.15 -0.02 -0.17 0.31 -0.08 0.17 0.17 -0.12 -0.19 -0.22 0.04 
Visual analogue pain rating -0.42 -0.34* -0.30 -0.33* -0.29 -0.34* -0.24 -0.50** -0.05 0.49** 0.19 0.57** -0.39 -0.10 0.19 0.12 
